Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-365
Overview: The chronic nature of irritable bowel syndrome (IBS) necessitates persistence when trialing treatment options. After reviewing key identifiers of IBS, we discuss a second-line treatment’s efficacy in reducing symptoms and improving quality of life for patients with continued IBS symptoms. Tune in for valuable insights to make informed recommendations for your patients.
Episode resource links:
- Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed (nih.gov)
- https://www.aafp.org/pubs/afp/issues/2005/1215/p2501.html
Guest: Mariyan L. Montaque, DNP, FNP-BC
Music Credit: Richard Onorato
Fler avsnitt av Frankly Speaking About Family Medicine
Visa alla avsnitt av Frankly Speaking About Family MedicineFrankly Speaking About Family Medicine med Pri-Med finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
